Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Objective Simple measures of type I interferon (IFN) activity constitute highly attractive biomarkers in systemic lupus erythematosus (SLE). We explore galectin-3-binding protein (G3BP) as a novel ...

Objective No studies have investigated the incidence and correlation of scarring and dyspigmentation across all cutaneous lupus erythematosus (CLE) categories and subtypes. As better characterisation ...

Objectives There is limited data on the clinical manifestations, serologic profile and outcomes of patients with APS in the Philippine setting. This study aimed to determine the clinical and serologic ...

Objectives Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells driving lupus disease activity, is approved for adult and ...

Objectives Hematologic abnormalities are common in systemic lupus erythematosus (SLE), both at disease onset and during its progression. We present a case of severe, corticosteroid-refractory ...

Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by unpredictable flares and multiorgan involvement, often leading to progressive functional decline.

Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a heterogeneous clinical spectrum. Gastrointestinal (GI) involvement is uncommon but clinically relevant, with ...

Objectives To map and summarize available evidence on the efficacy and safety of anifrolumab across the different subtypes of cutaneous lupus erythematosus (CLE). Methods A scoping review was ...

Objectives Olfactory dysfunction is a relatively frequent manifestation in Systemic Lupus Erythematosus (SLE). This study aimed to evaluate the prevalence of smell impairment in SLE patients and its ...

Objectives This study aimed to evaluate the prevalence of specific autoantibodies in asymptomatic first-degree relatives of Systemic Lupus Erythematosus patients compared to healthy controls. Methods ...

Objectives Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin condition with no approved targeted treatments. Afimetoran – a first-in-class, once daily oral, selective, equipotent, ...